Dose-response effect of somatostatin-14 on human basal pancreatic hormones

B. Annibale, G. Delle Fave, F. Barbetti, L. De Magistris, M. Puoti, E. Giordano, F. Leonetti, G. Tamburrano

Research output: Contribution to journalArticlepeer-review


The effect of increased doses of Somatostatin-14 (3,10, 30,100, 300 μg/h) on basal release of insulin, pancreatic glucagon and pancreatic polypeptide (PP) was investigated on eight normal volunteers. Levels of Somatostatinlike immunoreactivity (SLI) was determined in order to correlate the increased SLI levels with the degree of islet hormone inhibition (r = 0.9947, p <0.01). By increasing the basal levels of SLI by one-third, a significant inhibition (p <0.01) of insulin, glucagon, and PP was noted (78.5, 78.6, 75.2%, respectively, on basal levels). The maximal effect was obtained with 300 μg/h for insulin, with 30 μg/h for glucagon and 100 μg/h for PP. In evaluating the relative inhibitory potency of somatostatin, expressed as ED50, the theoretic potency of somatostatin on each peptide had similar values, ranging from 30 to 10 μg/h. The present data show that a minimal peripheric increase in SLI is able to regulate basal islet pancreatic hormones.

Original languageEnglish
Pages (from-to)551-556
Number of pages6
Issue number5
Publication statusPublished - 1987


  • Endocrine pancreas
  • Glucagon
  • Insulin
  • Pancreatic polypeptide
  • Somatostatin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Internal Medicine
  • Gastroenterology


Dive into the research topics of 'Dose-response effect of somatostatin-14 on human basal pancreatic hormones'. Together they form a unique fingerprint.

Cite this